# Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Canonical URL: https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-phase-ii-covalent-111-data-in-type-2-diabetes-at-the-19th-international-conference-on-advanced-technologies-and-treatments-for-diabetes-2026
Ticker: BMEA
Company: Biomea Fusion
Source: Biomea Fusion
Published: 2026-03-14 08:30 EST
Original Source URL: https://investors.biomeafusion.com
## Summary

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on

## Article Body
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on
## Recent Company News
- 2026-06-03 12:00 EST — [Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity) — Source: Biomea Fusion
- 2026-05-11 20:55 EST — [Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Biomea Fusion
- 2026-05-05 21:51 EST — [Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions) — Source: Biomea Fusion
- 2026-04-27 21:37 EST — [Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment) — Source: Biomea Fusion
- 2026-03-31 11:00 EST — [Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies) — Source: Biomea Fusion
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)